LICENSE AND COLLABORATION AGREEMENT by and between PERCEPTION NEUROSCIENCE, INC. and OTSUKA PHARMACEUTICAL CO., LTD. Dated as of March 11, 2021License and Collaboration Agreement • May 27th, 2021 • ATAI Life Sciences B.V. • Pharmaceutical preparations • New York
This License and Collaboration Agreement (this “Agreement”) is entered into as of March 11, 2021 (the “Effective Date”) by and between Perception Neuroscience, Inc., a company organized and existing under the laws of Delaware, having an address at 180 Varick Street, Suite 637, New York, NY 10014, USA (“Perception”) and Otsuka Pharmaceutical Co., Ltd., a company organized and existing under the laws of Japan, having an address at 2-9, Kanda Tsukasa-machi, Chiyoda-ku, Tokyo 101-8535, Japan (“Otsuka”). Perception and Otsuka are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. FSV7, INC. SERIES A PREFERRED STOCK PURCHASE AGREEMENT November 6, 2020Series a Preferred Stock Purchase Agreement • May 27th, 2021 • ATAI Life Sciences B.V. • Pharmaceutical preparations • Delaware
THIS PREFERRED STOCK PURCHASE AGREEMENT (this “Agreement”), is made as of November 6, 2020, by and among FSV7, Inc., a Delaware corporation (the “Company”), and the investors listed on Exhibit A attached to this Agreement (each a “Purchaser” and together the “Purchasers”).
